摘要
目的分析中国全球基金耐多药结核病项目(下简称"项目")阶段性实施结果,总结"项目"实施过程中的耐多药肺结核诊断、治疗和管理策略的成功经验与不足,提出改进措施,为我国下一步耐多药结核病控制工作提供借鉴。方法收集"项目"执行期间的相关报表,进行回顾性分析。结果截至2010年6月,共筛查耐多药肺结核可疑者13 281例,培养13 163例,培养阳性进行药敏试验8 202例,确诊1 756例,纳入治疗994例。广东和湖北省纳入治疗患者6个月痰涂片阴转率为66.4%,痰培养阴转率为62.2%。所有接受治疗患者的不良反应发生率为62.6%。结论通过"项目"的实施验证,以地(市)为中心开展耐多药结核病治疗管理的模式、标准化治疗方案为主的治疗策略是可行的。耐多药结核病诊治水平,不良反应管理等方面有待进一步加强。
Objective To analyze and evaluate the implementation of Global Fund China multi- drug resistant tuberculosis（MDR-TB） project in order to share experiences, analyze the weakness, find out the possible solutions and provide reference for China TB control work. Methods Monthly and quarterly reports are all collected for retrospective analysis. Results By the end of June 2010, a total of 13 281 MDR-TB suspects were screened,among which 13 163 cases received culture, 8 202 performed drug susceptibility test（DST）. 1 756 MDR-TB patients were confirmed, 994 cases were recruited for treatment. For patients completed 6 months treatment, 71.5% showed sputum negative conversion. For patients involed in treatment in Guangdong and Hubei, 66.4% showed sputum smear negative conversion, 62.6% showed culture negative conversion by the end of 6 month of treatment. The rate of adverse drug response was 62.6%. Conclusions This project proves that the model which takes prefectural level as MDR treatment center, uses the standard treatment regimen as the main strategy is feasible For the next step MDR-TB control work, we should strengthen the following aspects, capacity building of MDR-TB diagnosis and treatment, adverse drug response management.
出处
《中国防痨杂志》
CAS
2010年第11期700-704,共5页
Chinese Journal of Antituberculosis
关键词
结核
肺/预防和控制
抗药性
多种
细菌
tuberculosis, pulmonary/prevention and control
drug resistance, multiple, bacterial
